Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
08 oct. 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
01 oct. 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
20 août 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
07 août 2024 16h11 HE | Catalyst Pharmaceuticals, Inc.
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
24 juil. 2024 08h05 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
22 juil. 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
30 mai 2024 13h41 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
28 mai 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
08 mai 2024 16h16 HE | Catalyst Pharmaceuticals, Inc.
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
01 mai 2024 08h00 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...